

CORTEX PHARMACEUTICALS INC/DE/
 Form 144/A
 August 17, 2011

OMB APPROVAL
 OMB Number: 3235-0101
 Expires: February 28, 2014
 Estimated average burden
 hours per response 1.00

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 144/A

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

SEC USE ONLY
 DOCUMENT SEQUENCE NO.

CUSIP NUMBER

WORK LOCATION

ATTENTION: *Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker.*

| | | | |
|-------------------------------------------------------|------------------------------------------|----------------------------------------------------|------------------------------------|
| 1 (a) NAME OF ISSUER (Please type or print) | | (b) IRS IDENT. NO. | (c) S.E.C. FILE NO. |
| Cortex Pharmaceuticals, Inc. | | 330303583 | 001-16467 |
| 1 (d) ADDRESS OF ISSUER | STREET CITY STATE | ZIP CODE | (e) TELEPHONE NO. AREA CODE NUMBER |
| | 15241 Barranca Parkway Irvine California | 92618 | 949 727-3157 |
| 2 (a) NAME OF PERSON FOR WHOSE ACCOUNT THE SECURITIES | (b) RELATIONSHIP TO | (c) ADDRESS | STREET CITY STATE ZIP CODE |
| ARE TO BE SOLD | ISSUER | | |
| Samyang Optics Co., Ltd. | 10% Shareholder | 654-4 Bongamdong, Masanhwiwongu, Changwonsi, Korea | |

INSTRUCTION: *The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the S.E.C. File Number.*

| 3(a) | (b) | SEC USE ONLY | (c) | (d) | (e) | (f) | (g) |
|--------------|---------------------------------|---------------|------------------|-----------|------------------|-------------------|--------------|
| Title of the | Name and Address of Each Broker | Broker-Dealer | Number of Shares | Aggregate | Number of Shares | Approximate | Name of Each |
| Class of | Through Whom the Securities are | File Number | or Other | Market | or Other Units | Date of Sale | Securities |
| Securities | to be Offered or Each Market | | Units | Value | Outstanding | (See instr. 3(f)) | Exchange |

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 144/A

| To Be Sold | Maker who is Acquiring the Securities | | To Be Sold (See instr. 3(d)) (See instr. 3(e)) (MO. DAY YR.) (See instr. 3(g)) | | | | |
|--------------|-----------------------------------------------------------------------------------------|--|--------------------------------------------------------------------------------|---------|----------|------------|-------------------------|
| Common Stock | Hanmi Asset Securities, Inc. 3600 Wilshire Blvd. Suite 2226 Los Angeles, CA 90010 | | (See instr. 3(c)) | 788,581 | \$55,201 | 78,858,197 | beginning 05/16/2011 |
| | | | | (1) | (2) | | |

INSTRUCTIONS:

1. (a) Name of issuer
- (b) Issuer's I.R.S. Identification Number
- (c) Issuer's S.E.C. file number, if any
- (d) Issuer's address, including zip code

- (e) Issuer's telephone number, including area code
2. (a) Name of person for whose account the securities are to be sold
- (b) Such person's relationship to the issuer (e.g., officer, director, 10% stockholder, or member of immediate family of any of the foregoing)
- (c) Such person's address, including zip code
3. (a) Title of the class of securities to be sold
- (b) Name and address of each broker through whom the securities are intended to be sold
- (c) Number of shares or other units to be sold (if debt securities, give the aggregate face amount)
- (d) Aggregate market value of the securities to be sold as of a specified date within 10 days prior to the filing of this notice
- (e) Number of shares or other units of the class outstanding, or if debt securities the face amount thereof outstanding, as shown by the most recent report or statement published by the issuer

- (f) Approximate date on which the securities are to be sold
- (g) Name of each securities exchange, if any, on which the securities are intended to be sold

Potential persons who are to respond to the collection of information contained in this form are not

required to respond unless the form displays a currently valid OMB control number.

SEC 1147 (08-07)

TABLE I SECURITIES TO BE SOLD

*Furnish the following information with respect to the acquisition of the securities to be sold
and with respect to the payment of all or any part of the purchase price or other consideration therefor:*

| Title of the Class | Date you Acquired | Nature of Acquisition Transaction | Name of Person from Whom Acquired <i>(If gift, also give date donor acquired)</i> | Amount of Securities Acquired | Date of Payment | Nature of Payment |
|-----------------------|----------------------|-----------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------|--------------------|----------------------|
| Common | 06/07/2010 (3) | Conversion from a convertible promissory note | Cortex Pharmaceuticals, Inc. | 14,527,212 (4) | 01/15/2010 (5) | cash |

INSTRUCTIONS: If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

TABLE II SECURITIES SOLD DURING THE PAST 3 MONTHS

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

| Name and Address of Seller | Title of Securities Sold | Date of Sale | Amount of Securities Sold | Gross Proceeds |
|------------------------------------------------------------------------------------------|--------------------------|--------------|------------------------------|----------------|
| Samyang Optics Co., Ltd. 654-4 Bongamdong, Masanhwiwongu, Changwonsi, Korea | Common Stock | May 2011 | 269,546 | \$33,102 |

REMARKS: (1) Based on closing price, \$0.07 as of 08/16/2011
(2) Shares as of 03/31/2011 as reported on Form10-Q
(3) Date of conversion from note
(4) 10,445,579 shares of common stocks and 4,081,633 shares issuable upon exercise of warrant
(5) The date of acquiring note

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 144/A

- This Form 144/A amends the Form 144 filed on May 18, 2011.

INSTRUCTIONS:

See the definition of person in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

ATTENTION: *The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.*

08/17/2011

/s/ Dong Hoon Kim

DATE OF NOTICE

(SIGNATURE)

DATE OF PLAN ADOPTION OR GIVING OF INSTRUCTION,

The notice shall be signed by the person for whose account the securities are to be sold. At least one copy of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.

IF RELYING ON RULE 10B5-1

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

SEC 1147 (02-08)